Iain Ross bought 200k shares on the Australian Exchange. Something is brewing.
Use Ctrl f and search "Novogen"
Dr. Stephen Palmer - Degenerative Diseases Program Director is presenting a poster at the American Society of Human Genetics in Baltimore in early October. That's the Jacob's Hope program.
Back in Feb Dr. Kelly stated several studies were being done in the Non-Oncology side that shareholders would see data from later in year. I believe we see some of those results soon. The company wants to see the warrants exercised.
The next big binary event will be the preclinical results of Anisina for the adult indications the company plans to target. This includes prostate cancer, which could pop the stock significantly. In addition, I anticipate some of data coming out from the Jacob's Hope side on studies that began earlier in the year. The company may also announce a new collaboration. In short, the company's valuation is just too low given the breadth of their pipeline.
I'm having issues posting the whole thing, but here is the link: http://hotcopper.com.au/threads/spoke-with-david-brown-via-phone-email-cso.2589061/?post_id=15940177#.VeokP5eNnNk
I posted this on HotCopper, but thought you guys would appreciate it too.
Dear Mr Thomson,
Professor Mor has forwarded me your email requesting information on Cantrixil – a Novogen product.
Prior to commencing a clinical trial, both Regulators and Hospital Human research ethics committees need to review a series of safety reports to be able to to correlate drug concentration with toxicity.
An approved safety evaluation program is standard practice for all experimental drugs. This can take 6-8 months to complete. As such we are in the process of completing this program.
Salient points from our recent market update are:
The planned Cantrixil safety and manufacturing programs currently being executed has been reviewed by the FDA
We are able to manufacture GLP material (drug substance and drug product) in sufficient quantities to complete our safety studies
Preliminary safety data in two mammalian species and pharmacology data has been reviewed by our Scientific Review Committee and members of our Medical Advisory Board
Both committees have reviewed the safety signals and their unanimous recommendation is that we proceed with our safety program as it stands.
Our Medical Advisory Board have made the observation that none of the safety signals generated to date are regarded as unmanageable in the clinic.
We are on track to completing this safety evaluation Q1 2015
It is understandable that folk from outside of the industry feel frustrated with this process. This is an internationally mandated process put in place to protect patients and ensure that all new medications are safe and efficacious. We are working as quickly as practicable, but we will not compromise on the safety testing of our drug candidates.
David M. Brown, B.App. Sc. (Hons), PhD
Novogen Group, Chief Scientific Officer
We also spoke on the phone and Dr. Brown called me here in California. He's very personable and easy to talk
Novogen has $45 million AUD in cash ($32 million USD)...It is one of the cheapest preclinical oncology companies out there with a potentially revolutionary group of drugs.